Based on these observations, we developed a mouse model of atrial fibrosis induced by continuous subcutaneous Ang‐II infusion to reveal whether PU.1 inhibition attenuates Ang‐II‐induced atrial fibrosis and vulnerability to AF via the TGF‐β1/Smads pathway. Here, TGFB1 is linked to atrial fibrillation.